Recurrent pneumonia among Japanese adults: disease burden and risk factors
Authors:
- on behalf of the Adult Pneumonia Study Group - Japan (APSG-J)O(on behalf of the Adult Pneumonia Study Group - Japan (APSG-J)
- Tomoko IshifujiTITomoko Ishifuji
- Eiichiro SandoESEiichiro Sando
- Norihiro KanekoNKNorihiro Kaneko
- Motoi SuzukiMSMotoi Suzuki
- Paul E. KilgorePaul E. Kilgore
- Koya AriyoshiKAKoya Ariyoshi
- Konosuke MorimotoKMKonosuke Morimoto
- Naoto HosokawaNHNaoto Hosokawa
- Makito YaegashiMYMakito Yaegashi
- Masahiro AoshimaMAMasahiro Aoshima
Open Access
- 11 January 2017
- journal article
- research article
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 17 (1) , 1-9
Abstract
In Japan and other societies with rapidly aging populations, recurrent pneumonia (RP) is a major clinical problem yet only limited information exists regarding the burden of this disease. A prospective study of adult pneumonia was conducted to investigate the incidence of RP and potential risk factors. From February 1, 2012 to January 31, 2013, patients aged ≥ 15 years who were diagnosed with pneumonia were prospectively enrolled in a representative community hospital located in central Japan. Patients were followed for one-year to evaluate the recurrence of pneumonia and characteristics associated with RP. Cox proportional hazards models were constructed to compute adjusted hazard ratios (aHR) and ascertain risk factors significantly associated with RP. In total, 841 patients with a median age of 73 years (range 15–101 years) were enrolled totaling 1,048 person-years of observation with a median follow-up time of 475 days. A total of 137 patients had at least one recurrent episode with an incidence rate of 13.1 per 100 person-years (95% confidence interval: 11.1–15.5). In multivariate analysis, a past history of pneumonia (aHR 1.95, 95% CI: 1.35–2.8), chronic pulmonary disease (aHR 1.86, 1.24–2.78) and inhaled corticosteroid usage (aHR 1.78, 1.12–2.84) and hypnotic/sedative medication usage (aHR 2.06, 1.28–3.31) were identified as independent risk factors for recurrent pneumonia, whereas angiotensin converting enzyme-inhibitors usage was associated with a reduction of the risk of RP (aHR 0.22, 0.05–0.91). The detection of P. aeruginosa was significantly associated with RP even after adjusting for chronic pulmonary diseases (aHR = 2.37). Recurrent pneumonia constitutes a considerable proportion of the pneumonia burden in Japan. A past history of pneumonia, chronic pulmonary disease, inhaled corticosteroid and hypnotic/sedative medication usage and detection of P. aeruginosa were identified as independent risk factors for recurrent pneumonia and special attention regarding the use of medications in this vulnerable population is needed to reduce the impact of this disease in aging populations.Keywords
Funding Information
- Pfizer
This publication has 41 references indexed in Scilit:
- Risk factors for community-acquired pneumonia in adults in Europe: a literature reviewThorax, 2013
- Use of Opioids or Benzodiazepines and Risk of Pneumonia in Older Adults: A Population‐Based Case–Control StudyJournal of the American Geriatrics Society, 2011
- Pharmacotherapy and the risk for community-acquired pneumoniaBMC Geriatrics, 2010
- Population-Based Study of the Epidemiology and the Risk Factors for Pseudomonas aeruginosa Bloodstream InfectionInfection, 2009
- Aetiology of, and risk factors for, recurrent community-acquired pneumoniaClinical Microbiology and Infection, 2009
- Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study resultsEuropean Respiratory Journal, 2009
- Risk factors and outcome of community‐acquired pneumonia due to Gram‐negative bacilliRespirology, 2008
- Indicators of Recurrent Hospitalization for Pneumonia in the ElderlyJournal of the American Geriatrics Society, 2004
- Risk of pneumonia in patients previously treated in hospital for pneumoniaThe Lancet, 1992
- Recurrent Pneumonia: A Review of 90 Adult PatientsScandinavian Journal of Infectious Diseases, 1992